Amneal says it is planning an early 2024 launch for its Pemrydi (pemetrexed) ready-to-use oncology injectable after the US Food and Drug Administration approved the product via the 505(b)(2) hybrid pathway.
Describing Pemrydi as “the first ready-to-use presentation of [this] key injectable,” Amneal said the product was indicated, in combination with...
Welcome to Generics Bulletin
Create an account to read this article
Already a subscriber?